CorMedix inc. Announces Customer Implementation

Core Insights - CorMedix Inc. is advancing the implementation of its product DefenCath with a Large Dialysis Organization (LDO) customer, targeting an initial patient base that is at least 50% larger than previously communicated [2][4] - The company has amended its agreement with the LDO customer to accommodate the anticipated increased utilization of DefenCath, expecting modest revenue contributions in June and growth in the latter half of 2025 [2][3] - Due to positive business developments, CorMedix has raised its second quarter net sales guidance from $31 million to a range of $35 million to $40 million [3] Company Overview - CorMedix Inc. focuses on developing and commercializing therapeutic products for life-threatening diseases, with its lead product DefenCath (taurolidine and heparin) approved by the FDA on November 15, 2023 [4] - The commercial launch of DefenCath began in inpatient settings in April 2024 and in outpatient settings in July 2024 [4] - The company plans to initiate clinical studies in Total Parenteral Nutrition and Pediatric patient populations in 2025 and aims to develop DefenCath as a catheter lock solution for other patient populations [4]